Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.